A Compound Enters the Prescription Drug Pathway
Placeholder: drug candidates face years of mandatory trials before sale.
- 10–15 yrs: Avg. drug approval timeline (placeholder caption)
- 3: Clinical trial phases required (placeholder caption)
- Mandatory: FDA pre-market review (placeholder caption)
- $1–2 B: Avg. development cost (placeholder caption)
Preclinical and trial gates
Placeholder: animal studies then Phase I–III human trials filter candidates.
FDA review and approval
Placeholder: agency reviewers must certify safety and efficacy data.
Placeholder highlight: drug approval requires proven, replicated clinical benefit.
GMP manufacturing standards
Placeholder: certified plants follow strict, inspected production controls.
The Same Molecule Reappears as a Dietary Supplement
Placeholder: relabeling shifts the compound into a far lighter regime.
- Not required: Pre-market FDA approval (placeholder caption)
- DSHEA 1994: Governing US framework (placeholder caption)
- No: Efficacy proof required (placeholder caption)
- Weeks: Market entry timeline (placeholder caption)
DSHEA and the supplement carve-out
Placeholder: 1994 law treats supplements unlike prescription drugs.
What manufacturers must avoid
Placeholder: labels must skip explicit disease-treatment claims.
Placeholder highlight: no agency verifies content before the bottle ships.
Post-market enforcement only
Placeholder: regulators act after problems surface, not before.
Comparing the Two Regulatory Pipelines
Placeholder: identical molecule, two very different checkpoint counts.
- 4–5: Drug pathway required gates (placeholder caption)
- 1–2: Supplement required gates (placeholder caption)
- Optional: Independent lab testing (placeholder caption)
- Rarely: NDI notification filed (placeholder caption)
Efficacy proof, side by side
Placeholder: drugs must prove benefit; supplements need not.
Manufacturing oversight, side by side
Placeholder: GMP inspection intensity differs sharply between tracks.
Placeholder highlight: toggle the pathway slider to compare gate counts.
Batch-to-Batch Content Variability Emerges
Placeholder: looser oversight lets actual dosing drift from the label.
- ~2–5%: Drug content variability (placeholder caption)
- 40–65%: Low-QC supplement variability (placeholder caption)
- 10–20%: High-QC supplement variability (placeholder caption)
- ~20%+: Products mislabeled (studies) (placeholder caption)
Why variability differs so much
Placeholder: no mandated potency testing lets drift go unnoticed.
Quality control still matters
Placeholder: better manufacturers voluntarily test and narrow the drift.
Placeholder highlight: QC level shifts the fuzz, but never to drug-level precision.
What Is Actually in the Bottle?
Placeholder: shoppers face real uncertainty absent from regulated drugs.
- High: Consumer content certainty (drug) (placeholder caption)
- Variable: Consumer content certainty (supp.) (placeholder caption)
- Elevated: Contamination risk reports (placeholder caption)
- Optional: Third-party seals available (placeholder caption)
Living with the gray zone
Placeholder: informed buyers seek independent verification where possible.
What could narrow the gap
Placeholder: mandatory testing and disclosure would shrink uncertainty.
Placeholder highlight: until rules change, the bottle remains a probability, not a promise.